MiR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF)

American Journal of Pathology

Volumn 182, Issue 5, 2013, Pages 1629-1639

  Zhang, Jinqiang ^a   Han, Chang ^a   Zhu, Hanqing ^a   Song, Kyoungsub ^a   Wu, Tong ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; MICRORNA 101; VASCULOTROPIN;

3' UNTRANSLATED REGION; ARTICLE; BILE DUCT CARCINOMA; CAPILLARY DENSITY; CARCINOGENESIS; CONTROLLED STUDY; EPITHELIUM CELL; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876569990     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.01.045     Document Type: Article

References (35)

1. B. Blechacz, and G.J. Gores Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment Hepatology 48 2008 308 321
2. A.E. Sirica Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy Hepatology 41 2005 5 15
3. T. Wu Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma Biochim Biophys Acta 1755 2005 135 150
4. E.P. Berthiaume, and J. Wands The molecular pathogenesis of cholangiocarcinoma Semin Liver Dis 24 2004 127 137
5. G. Fava, and I. Lorenzini Molecular pathogenesis of cholangiocarcinoma Int J Hepatol 2012 2012 630543
6. K.N. Lazaridis, and G.J. Gores Primary sclerosing cholangitis and cholangiocarcinoma Semin Liver Dis 26 2006 42 51
7. H. Malhi, and G.J. Gores Cholangiocarcinoma: modern advances in understanding a deadly old disease J Hepatol 45 2006 856 867
8. T. Patel Cholangiocarcinoma-controversies and challenges Nat Rev Gastroenterol Hepatol 8 2011 189 200
9. G.L. Tyson, and H.B. El-Serag Risk factors for cholangiocarcinoma Hepatology 54 2011 173 184
10. D. Tang, H. Nagano, H. Yamamoto, H. Wada, M. Nakamura, M. Kondo, H. Ota, S. Yoshioka, H. Kato, B. Damdinsuren, S. Marubashi, A. Miyamoto, Y. Takeda, K. Umeshita, K. Dono, K. Wakasa, and M. Monden Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance Oncol Rep 15 2006 525 532
11. S.S. Glaser, E. Gaudio, and G. Alpini Vascular factors, angiogenesis and biliary tract disease Curr Opin Gastroenterol 26 2010 246 250
12. S. Gately The contributions of cyclooxygenase-2 to tumor angiogenesis Cancer Metastasis Rev 19 2000 19 27
13. N. Hayashi, H. Yamamoto, N. Hiraoka, K. Dono, Y. Ito, J. Okami, M. Kondo, H. Nagano, K. Umeshita, M. Sakon, N. Matsuura, S. Nakamori, and M. Monden Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm Hepatology 34 2001 638 650
14. K. Endo, B.I. Yoon, C. Pairojkul, A.J. Demetris, and A.E. Sirica ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions Hepatology 36 2002 439 450
15. S. Chariyalertsak, V. Sirikulchayanonta, D. Mayer, A. Kopp-Schneider, G. Furstenberger, F. Marks, and K. Muller-Decker Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma Gut 48 2001 80 86
16. A.E. Sirica, G.H. Lai, K. Endo, Z. Zhang, and B.I. Yoon Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets Semin Liver Dis 22 2002 303 313
17. A.E. Sirica, G.H. Lai, and Z. Zhang Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies J Gastroenterol Hepatol 16 2001 363 372
18. M.A. Valencia-Sanchez, J. Liu, G.J. Hannon, and R. Parker Control of translation and mRNA degradation by miRNAs and siRNAs Genes Dev 20 2006 515 524
19. D. Betel, A. Koppal, P. Agius, C. Sander, and C. Leslie Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites Genome Biol 11 2010 R90
20. D. Betel, M. Wilson, A. Gabow, D.S. Marks, and C. Sander The microRNA.org resource: targets and expression Nucleic Acids Res 36 2008 D149 D153
21. S.L. Au, C.C. Wong, J.M. Lee, D.N. Fan, F.H. Tsang, I.O. Ng, and C.M. Wong Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis Hepatology 56 2012 622 631
22. A. Strillacci, C. Griffoni, P. Sansone, P. Paterini, G. Piazzi, G. Lazzarini, E. Spisni, M.A. Pantaleo, G. Biasco, and V. Tomasi MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells Exp Cell Res 315 2009 1439 1447
23. H. Su, J.R. Yang, T. Xu, J. Huang, L. Xu, Y. Yuan, and S.M. Zhuang MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity Cancer Res 69 2009 1135 1142
24. K.L. Thu, R. Chari, W.W. Lockwood, S. Lam, and W.L. Lam miR-101 DNA copy loss is a prominent subtype specific event in lung cancer J Thorac Oncol 6 2011 1594 1598
25. E. Vilardo, C. Barbato, M. Ciotti, C. Cogoni, and F. Ruberti MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons J Biol Chem 285 2010 18344 18351
26. J. Hou, L. Lin, W. Zhou, Z. Wang, G. Ding, Q. Dong, L. Qin, X. Wu, Y. Zheng, Y. Yang, W. Tian, Q. Zhang, C. Wang, S.M. Zhuang, L. Zheng, A. Liang, W. Tao, and X. Cao Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma Cancer Cell 19 2011 232 243
27. E.J. Adams, J.A. Green, A.H. Clark, and J.H. Youngson Comparison of different scoring systems for immunohistochemical staining J Clin Pathol 52 1999 75 77
28. J. Zhang, C. Han, and T. Wu MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin Gastroenterology 143 2012 246 256.e248
29. X. Wang, and R.D. Klein Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway Mol Carcinog 46 2007 912 923
30. D. Bradbury, D. Clarke, C. Seedhouse, L. Corbett, J. Stocks, and A. Knox Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites J Biol Chem 280 2005 29993 30000
31. M.A. Iniguez, A. Rodriguez, O.V. Volpert, M. Fresno, and J.M. Redondo Cyclooxygenase-2: a therapeutic target in angiogenesis Trends Mol Med 9 2003 73 78
32. R.M. Abdel-Majid, and J.S. Marshall Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells J Immunol 172 2004 1227 1236
33. S.H. Chang, C.H. Liu, M.T. Wu, and T. Hla Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor Prostaglandins Other Lipid Mediat 76 2005 48 58
34. X.H. Liu, A. Kirschenbaum, M. Lu, S. Yao, A. Dosoretz, J.F. Holland, and A.C. Levine Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line J Biol Chem 277 2002 50081 50086
35. A. Strillacci, M.C. Valerii, P. Sansone, C. Caggiano, A. Sgromo, L. Vittori, M. Fiorentino, G. Poggioli, F. Rizzello, M. Campieri, and E. Spisni Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells J Pathol 229 2013 379 389